Rempenault C, Combe B, Barnetche T, et al. - Researchers systematically searched MEDLINE (via PubMed), Embase, Cochrane Library, and the American College of Rheumatology and European League Against Rheumatism annual scientific meeting abstracts for studies available up to November 2017 contrasting the effectiveness of Hydroxychloroquine (HCQ) in people with RA, in monotherapy or combined with other conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) in order to evaluate the up to date literature on the clinical and structural effectiveness of HCQ in the joints of individuals with RA. To meet with inclusion criteria, the literature search revealed 197 articles and abstracts of potential interest and 11 studies. It was found that in addition to its metabolic benefit, combining HCQ with other DMARDs could give some clinical improvement in people with RA and inadequate response to previous csDMARDs.